- Home
- DBL vs TNXP Comparison
DBL vs TNXP Comparison
Compare DBL & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBL
- TNXP
- Stock Information
- Founded
- DBL 2011
- TNXP 2007
- Country
- DBL United States
- TNXP United States
- Employees
- DBL N/A
- TNXP N/A
- Industry
- DBL
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- DBL
- TNXP Health Care
- Exchange
- DBL Nasdaq
- TNXP Nasdaq
- Market Cap
- DBL 287.6M
- TNXP 335.6M
- IPO Year
- DBL N/A
- TNXP N/A
- Fundamental
- Price
- DBL $15.42
- TNXP $37.98
- Analyst Decision
- DBL
- TNXP Buy
- Analyst Count
- DBL 0
- TNXP 1
- Target Price
- DBL N/A
- TNXP $70.00
- AVG Volume (30 Days)
- DBL 61.0K
- TNXP 2.2M
- Earning Date
- DBL 01-01-0001
- TNXP 08-11-2025
- Dividend Yield
- DBL 8.67%
- TNXP N/A
- EPS Growth
- DBL N/A
- TNXP N/A
- EPS
- DBL N/A
- TNXP N/A
- Revenue
- DBL N/A
- TNXP $9,831,000.00
- Revenue This Year
- DBL N/A
- TNXP $22.87
- Revenue Next Year
- DBL N/A
- TNXP $711.66
- P/E Ratio
- DBL N/A
- TNXP N/A
- Revenue Growth
- DBL N/A
- TNXP N/A
- 52 Week Low
- DBL $13.75
- TNXP $6.76
- 52 Week High
- DBL $15.70
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- DBL 58.54
- TNXP 43.12
- Support Level
- DBL $15.23
- TNXP $34.50
- Resistance Level
- DBL $15.46
- TNXP $53.55
- Average True Range (ATR)
- DBL 0.10
- TNXP 6.41
- MACD
- DBL 0.01
- TNXP -1.97
- Stochastic Oscillator
- DBL 68.97
- TNXP 11.06
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.